Chemotherapy
Fujita, S.; Kotake, K.
Nihon Rinsho. Japanese Journal of Clinical Medicine 72(1): 102-107
2014
ISSN/ISBN: 0047-1852 PMID: 24597356 Document Number: 677728
Chemotherapy for colorectal cancer has improved greatly and survival rate is improving. Now, we have many effective but toxic regimens (FOLFOX, CapeOX, FOLFIRI, FOLFOXIRI with or without bevacizumab or cetuximab or panitumumab) and regorafenib, a multikinase inhibitor, can be used for third- or forth-line treatment. Treatments should be tailored to an individual patient according to tumor characteristics and patient conditions. Conversion therapy is secondary surgery after most active induction chemotherapy, e.g., FOLFOX with cetuximab. Conversion rate is about 10%. Adjuvant chemotherapy is indicated for stage III patients. 5FU+LV, UFT+LV, capecitabine, FOLFOX, CapeOX and S-1 are available in the adjuvant setting. Regimens including oxaliplatin should be prescribed to high-risk stage III patients, because of oxaliplatin toxicity.